GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2007

Unigene Inks Supply Deal With Novartis

  • Unigene Laboratories will receive $2.5 million to supply Novartis with specified quantities of a bulk peptide necessary for development of its osteoporosis treatment.

    Unigene will develop a process for the peptide, and Novartis will have the opportunity to purchase additional quantities as necessary.

    In 2004, Novartis exclusively licensed Unigene's technology to manufacture another peptide, calcitonin, and it now runs the scaled-up process at its manufacturing facility in Kundl, Austria.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »